Third FDA Form 483 in Two Months Hits Dr. Reddy's
RDY is trading near its 52-week low of $11.36 (9.6% above the low).
Summary
Dr. Reddy's received a new Form 483 with four observations from the USFDA after an inspection of its Bachupally formulations facility, marking the third such notice in two months.
Key Events · Product Development and Regulatory · RDY
-
Third Form 483 in Two Months
USFDA issued a Form 483 with four observations after inspecting the FTO-3 formulations facility in Bachupally, Hyderabad from August 6–14, 2026.
-
Pattern of Regulatory Findings
This follows a Form 483 with seven observations at a biologics facility on June 26 and another with three observations at Srikakulam on July 29, indicating systemic quality issues.
-
Potential Impact on Approvals
Repeated observations may slow pending product approvals and increase remediation costs, adding to existing supply chain challenges from the semaglutide API quality issue.
-
Company Response
Dr. Reddy's stated it will address the observations within the stipulated timeline, but no specific remediation plan or timeline was disclosed.
Analysis · RDY · Life Sciences
The USFDA issued a Form 483 with four observations after inspecting Dr. Reddy's FTO-3 formulations facility in Bachupally, Hyderabad. This is the third Form 483 disclosed since late June, following seven observations at a biologics facility and three at Srikakulam. The repeated regulatory findings across multiple sites raise concerns about systemic quality control issues, which could delay product approvals, increase remediation costs, and damage the company's reputation with the FDA.
At the time of this filing, RDY was trading at $12.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $10.5B. The 52-week trading range was $11.36 to $15.67. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.